Comparative effectiveness of 5-fluorouracil with and without oxaliplatin in the treatment of colorectal cancer in clinical practice.
暂无分享,去创建一个
[1] Debra L. Bynum,et al. Adjuvant chemotherapy in older patients with stage III colon cancer: an underused lifesaving treatment. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] K. Kahn,et al. Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] M. O’connell,et al. Comparative evaluation of capecitabine or infusional leucovorin/5-fluorouracil (LV/5-FU) with or without oxaliplatin (Ox) for stage III colon cancer (CC): A pooled analysis of individual patient data from four randomized controlled trials. , 2012 .
[4] K. Kahn,et al. Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer. , 2012, Journal of the National Cancer Institute.
[5] R. Winterhalder,et al. Self-Reported Compliance with Capecitabine: Findings from a Prospective Cohort Analysis , 2011, Oncology.
[6] H. Schmoll. Do we need oncology trials tailored for the elderly or frail? , 2011, The Lancet.
[7] R. Glynne-Jones,et al. What is the Impact of the Addition of Oxaliplatin to 5-Fluorouracil–Based Preoperative Chemoradiation in Rectal Cancer? , 2011 .
[8] T. Conroy,et al. Capecitabine plus oxaliplatin (XELOX) versus 5‐fluorouracil/leucovorin plus oxaliplatin (FOLFOX‐6) as first‐line treatment for metastatic colorectal cancer , 2011, International journal of cancer.
[9] P. Gibbs,et al. Dose rounding of chemotherapy in colorectal cancer: An analysis of clinician attitudes and the potential impact on treatment costs , 2010, Asia-Pacific journal of clinical oncology.
[10] Christophe Hennequin,et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Andrew R Willan,et al. Optimal clinical trial design using value of information methods with imperfect implementation. , 2009, Health economics.
[12] S. Yun,et al. Compliance and Effective Management of the Hand-Foot Syndrome in Colon Cancer Patients Receiving Capecitabine as Adjuvant Chemotherapy , 2009, Yonsei medical journal.
[13] Ann Partridge,et al. Patient adherence and persistence with oral anticancer treatment , 2009, CA: a cancer journal for clinicians.
[14] Y. Bang,et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] K. Kahn,et al. Adjuvant chemotherapy for stage III colon cancer: do physicians agree about the importance of patient age and comorbidity? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] W. Scheithauer,et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] J. Kopec,et al. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Andrew R Willan,et al. Expected value of information and decision making in HTA. , 2007, Health economics.
[19] Ralph B D'Agostino,et al. Estimating treatment effects using observational data. , 2007, JAMA.
[20] Laura-Mae Baldwin,et al. Completion of therapy by Medicare patients with stage III colon cancer. , 2006, Journal of the National Cancer Institute.
[21] J. Feliu,et al. XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer , 2006, British Journal of Cancer.
[22] Markus Abt,et al. Capecitabine as adjuvant treatment for stage III colon cancer. , 2005, The New England journal of medicine.
[23] A. Zaslavsky,et al. Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] R. Schilsky,et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[25] A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. , 2001, The New England journal of medicine.
[26] A A Stinnett,et al. Net Health Benefits , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.
[27] David A. Schoenfeld,et al. Partial residuals for the proportional hazards regression model , 1982 .
[28] David A. Schoenfeld,et al. Chi-squared goodness-of-fit tests for the proportional hazards regression model , 1980 .